Maxcyte (MXCT) Operating Expenses (2020 - 2025)
Historic Operating Expenses for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $19.4 million.
- Maxcyte's Operating Expenses fell 447.04% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.1 million, marking a year-over-year decrease of 525.93%. This contributed to the annual value of $82.7 million for FY2024, which is 249.99% down from last year.
- As of Q3 2025, Maxcyte's Operating Expenses stood at $19.4 million, which was down 447.04% from $21.2 million recorded in Q2 2025.
- Over the past 5 years, Maxcyte's Operating Expenses peaked at $22.2 million during Q1 2024, and registered a low of $10.7 million during Q2 2021.
- For the 5-year period, Maxcyte's Operating Expenses averaged around $18.1 million, with its median value being $19.4 million (2025).
- Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 6038.19% in 2022, then tumbled by 1295.75% in 2024.
- Maxcyte's Operating Expenses (Quarter) stood at $13.9 million in 2021, then increased by 26.99% to $17.6 million in 2022, then increased by 25.87% to $22.2 million in 2023, then fell by 12.96% to $19.3 million in 2024, then increased by 0.36% to $19.4 million in 2025.
- Its last three reported values are $19.4 million in Q3 2025, $21.2 million for Q2 2025, and $21.2 million during Q1 2025.